Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesidolumab - MorphoSys

Drug Profile

Tesidolumab - MorphoSys

Alternative Names: LFG-316; NOV-4

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys; Novartis
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Discontinued Choroiditis; Dry age-related macular degeneration; Panuveitis; Thrombotic microangiopathy; Wet age-related macular degeneration

Most Recent Events

  • 11 Oct 2018 Discontinued - Phase-II for Choroiditis in United Kingdom, USA (Intravitreous)
  • 11 Oct 2018 Discontinued - Phase-II for Dry age-related macular degeneration (Combination therapy) in USA (Intravitreous)
  • 11 Oct 2018 Discontinued - Phase-II for Dry age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top